Pacific Biosciences of California (PACB) ended the recent trading session at $1.22, demonstrating a +1.67% swing from the preceding day's closing price. The stock's change was less than the S&P 500's ...

Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00.

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 20 cents in fourth-quarter 2024, narrower than the year-ago adjusted loss of 27 ...

New York State Common Retirement Fund raised its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – ...

3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever PACB stock opened at $1.56 on Tuesday. Pacific Biosciences of California has a 12-month low of $1.16 ...

Pacific Biosciences' Q4'24 results were another disappointment ... Growth in clinical and diagnostic markets will help, but not right away, and PACB is likely to remain below $100M in annualized ...

Pacific Biosciences of California (PACB) came out with a quarterly loss ... The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings ...

I will be discussing non-GAAP results, which include non-cash stock-based compensation expense ... and NIH funding uncertainty. For Asia-Pacific, revenue of approximately $8.9 million decreased ...